Cellectar shareholders approve reverse stock split, re-elect directors

Cellectar Biosciences, Inc.

Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.
Ratified Deloitte & Touche as independent auditor for FY2025 with 16,651,803 votes for, 219,578 against.
Approved reverse stock split of common stock at ratio 1:10 to 1:30, as determined by Board; 13,464,719 for.
Approved non-binding advisory vote on named executive officer compensation: 5,050,203 for, 2,230,519 against.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.